Diabetes Drug Improves Parkinson’s Motor Symptoms in Small Trial
Motor symptoms slightly improved in 31 patients taking exenatide for 48 weeks, while the placebo group worsened. The effect persisted three months after treatment stopped.
6389 RESULTS
Sort By:
Motor symptoms slightly improved in 31 patients taking exenatide for 48 weeks, while the placebo group worsened. The effect persisted three months after treatment stopped.
At AAIC 2017, scientists offered new clues on sleep and AD neuropathology. They identified parts of the brain that may be involved and highlighted the benefits of treating sleep disorders.
Progenitors in cortical spheroids, cultured for nearly two years, morph into mature astrocytes, allowing researchers to study this process in vitro.
Progranulin yields multiple granulins in cells that persist in lysosomes and could be key to preventing FTD.
Another paper reports that tau forms liquid droplets, and does so more readily when phosphorylated. What this portends for tangle formation inside of neurons remains to be seen.
Rather than changing one by one, many biomarkers—including cognition, tau PET, hippocampal atrophy, and CSF p-tau—shift together, around the time of symptom onset in young adults with familial AD.
TIA1 mutations promote phase separation, generate a signature TDP-43 pathology.
AAIC presentations identified early imaging changes in aging and AD, and reinforced the idea that CSF markers change little over the short term.
Tamping down a cell stress response saves neurons from degenerating while helping mice retain both their strength and their wits.
Danish study correlates higher natural levels of lithium to lower incidence of Alzheimer’s disease
Hsp90, a protein chaperone that helps misfold tau, enlists the co-chaperone Aha1 in the process. Could crippling Aha1 reduce tau aggregation?
Researchers at AAIC presented several imaging measures that may help explain the phenomenon of preserved cognition in the face of AD pathology.
Idalopirdine is out. Next up, a handful of secretase inhibitors, other small molecules, and immunotherapies for Aβ and tau seem safe in Phases 1 and 2.
Three BACE inhibitors, a γ-secretase modulator, and a phosphodiesterase inhibitor appeared safe in Phase 1 trials.
Phase 1 clinical data presented at AAIC 2017 suggest few serious adverse events.
No filters selected